PD ISO/TS 16782:2016



BSI Standards Publication

Clinical laboratory testing — Criteria for acceptable lots of dehydrated Mueller-Hinton agar and broth for antimicrobial susceptibility testing



National foreword

This Published Document is the UK implementation of ISO/TS 16782:2016.

The UK participation in its preparation was entrusted to Technical Committee CH/212, IVDs.

A list of organizations represented on this committee can be obtained on request to its secretary.

This publication does not purport to include all the necessary provisions of a contract. Users are responsible for its correct application.

© The British Standards Institution 2016. Published by BSI Standards Limited 2016

ISBN 978 0 580 95546 4 ICS 11.100.20

Compliance with a British Standard cannot confer immunity from legal obligations.

This Published Document was published under the authority of the Standards Policy and Strategy Committee on 30 November 2016.

Amendments/corrigenda issued since publication

Date Text affected

PD ISO/TS 16782:2016

TECHNICAL SPECIFICATION

ISO/TS 16782

First edition 2016-10-15

Clinical laboratory testing — Criteria for acceptable lots of dehydrated Mueller-Hinton agar and broth for antimicrobial susceptibility testing

Détermination de la sensibilité aux antibiotiques — Critères d'acceptabilité pour les lots d'agar déshydraté et de bouillon Mueller-Hinton pour déterminer la sensibilité aux antibiotiques



PD ISO/TS 16782:2016 **ISO/TS 16782:2016(E)**



COPYRIGHT PROTECTED DOCUMENT

 $\, @ \,$ ISO 2016, Published in Switzerland

All rights reserved. Unless otherwise specified, no part of this publication may be reproduced or utilized otherwise in any form or by any means, electronic or mechanical, including photocopying, or posting on the internet or an intranet, without prior written permission. Permission can be requested from either ISO at the address below or ISO's member body in the country of the requester.

ISO copyright office Ch. de Blandonnet 8 • CP 401 CH-1214 Vernier, Geneva, Switzerland Tel. +41 22 749 01 11 Fax +41 22 749 09 47 copyright@iso.org www.iso.org

Coı	ntent	S Pa	age
Fore	word		iv
Intro	oductio	n	v
1	Scope	e	1
2	-		
3			
4			
	4.1 4.2 4.3 4.4 4.5	Components of Mueller-Hinton broth Physical and chemical characteristics 4.2.1 Dehydrated powder or granules 4.2.2 Prepared broth medium 4.2.3 Cation supplementation and content for MHB 4.2.4 Other medium components 4.2.5 Specific adjustments required by the manufacturer Manufacturers protocol for testing production lots of dehydrated Mueller-Hinton broth. Interpreting the results Evaluating the results	3 3 4 4 4 5 5
5	5.1 5.2 5.3 5.4 5.5	Components of Mueller-Hinton agar Physical and chemical characteristics 5.2.1 Dehydrated powder or granules 5.2.2 Prepared agar medium 5.2.3 Cation supplementation and content for MHA 5.2.4 Other medium components 5.2.5 Specific adjustments required by the manufacturer Manufacturer's protocol for testing production lots of dehydrated Mueller-Hinton agar. Interpreting the results	6 6 7 7 7 8
6			11
Anno	ex A (inf	formative) Mueller-Hinton medium	12
Ann	Requirements for Mueller-Hinton broth34.1Components of Mueller-Hinton broth34.2Physical and chemical characteristics34.2.1Dehydrated powder or granules34.2.2Prepared broth medium44.2.3Cation supplementation and content for MHB44.2.4Other medium components44.2.5Specific adjustments required by the manufacturer44.3Manufacturers protocol for testing production lots of dehydrated Mueller-Hinton broth 554.4Interpreting the results54.5Evaluating the results6Requirements for Muller-Hinton agar65.1Components of Mueller-Hinton agar65.2Physical and chemical characteristics665.2.1Dehydrated powder or granules65.2.2Prepared agar medium75.2.3Cation supplementation and content for MHA75.2.4Other medium components75.2.5Specific adjustments required by the manufacturer75.3Manufacturer's protocol for testing production lots of dehydrated Mueller-Hinton agar85.4Interpreting the results85.5Evaluating the results85.5Evaluating the results10Testing new antimicrobial agents with production lots of dehydrated Mueller-Hinton broth or agar11Inex A (informative) Mueller-Hinton medium12Inex B (informative) Preparing co		
Anno	ex C (inf	formative) Suggested data sheet for testing of production lots	16
Anno	ex D (inf	formative) Label statement	19
Bibli	Normative reference	20	

Foreword

ISO (the International Organization for Standardization) is a worldwide federation of national standards bodies (ISO member bodies). The work of preparing Technical Specifications is normally carried out through ISO technical committees. Each member body interested in a subject for which a technical committee has been established has the right to be represented on that committee. International organizations, governmental and non-governmental, in liaison with ISO, also take part in the work. ISO collaborates closely with the International Electrotechnical Commission (IEC) on all matters of electrotechnical standardization.

The procedures used to develop this document and those intended for its further maintenance are described in the ISO/IEC Directives, Part 1. In particular the different approval criteria needed for the different types of ISO documents should be noted. This document was drafted in accordance with the editorial rules of the ISO/IEC Directives, Part 2 (see www.iso.org/directives).

Attention is drawn to the possibility that some of the elements of this document may be the subject of patent rights. ISO shall not be held responsible for identifying any or all such patent rights. Details of any patent rights identified during the development of the document will be in the Introduction and/or on the ISO list of patent declarations received (see www.iso.org/patents).

Any trade name used in this document is information given for the convenience of users and does not constitute an endorsement.

For an explanation on the meaning of ISO specific terms and expressions related to conformity assessment, as well as information about ISO's adherence to the WTO principles in the Technical Barriers to Trade (TBT) see the following URL: Foreword - Supplementary information

The committee responsible for this document is ISO/TC 212, *Clinical laboratory testing and in vitro diagnostic test systems.*

Introduction

Historically, although various media have been recommended for susceptibility testing, Mueller-Hinton broth (MHB) has been selected as the medium for the reference broth microdilution minimum inhibitory concentration (MIC) method (ISO 20776-1) and Mueller-Hinton agar (MHA) is most widely used for disc diffusion testing of rapidly growing bacteria.

Mueller-Hinton medium provides satisfactory growth of most non-fastidious pathogens, acceptable batch-to-batch reproducibility, low sulfonamide, trimethoprim, and tetracycline inhibitors and a large amount of data has been collected from antimicrobial susceptibility tests with this medium over several decades.

This International Standard is the result of an effort to establish a standard description and protocol by which manufacturers of dehydrated Mueller-Hinton agar (dMHA) and broth (dMHB) may determine its acceptable performance characteristics.

The results of testing conform to defined quality control limit ranges for each combination of antimicrobial agent and quality control strains. Each production lot is tested at least against these combinations of antimicrobial agents and quality control strains.

This Technical Specification has been developed in part based upon two Clinical and Laboratory Standards Institute (CLSI) documents, CLSI M6-A2[1] (protocols for evaluating dehydrated Mueller-Hinton agar) and CLSI M32-P[2] (evaluation of lots of dehydrated Mueller-Hinton broth for antimicrobial susceptibility testing) with permission. Upon publication of ISO 16782, CLSI documents M6-A2[1] and M32-P[2] will no longer be available. Manufacturers can follow ISO 16782 to assess the performance characteristics of their production lots of dMHA and dMHB.

Clinical laboratory testing — Criteria for acceptable lots of dehydrated Mueller-Hinton agar and broth for antimicrobial susceptibility testing

1 Scope

This Technical Specification provides a standard description of the physical properties of dehydrated Mueller-Hinton broth (dMHB) and Mueller-Hinton agar (dMHA) and performance criteria by which manufacturers can assess the performance characteristics of their production lots of dMHA and dMHB. Production lots of broth or agar can then be utilized by all users, including *in vitro* susceptibility testing device manufacturers, as the test medium for performance of antimicrobial susceptibility testing.

This Technical Specification does not address supplements (e.g. blood or blood products) that are added to the medium to support growth of fastidious bacteria[3][4][5][6]. Those additives are provided after the dehydrated medium is prepared in its liquid state as a final product and fall outside of the scope of this Technical Specification. Although dMHA can be used for determination of MICs using the agar dilution method[4][6] or the gradient diffusion method, this Technical Specification only includes performance testing of dMHA using disc diffusion methodology as described by the Clinical and Laboratory Standards Institute (CLSI)[5] and European Committee on Antimicrobial Susceptibility Testing (EUCAST)[3].

2 Normative reference

The following documents, in whole or in part, are normatively referenced in this document and are indispensable for its application. For dated references, only the edition cited applies. For undated references, the latest edition of the referenced document (including any amendments) applies.

ISO 20776-1:2006, Clinical laboratory testing and in vitro diagnostic test systems — Susceptibility testing of infectious agents and evaluation of performance of antimicrobial susceptibility test devices — Part 1: Reference method for testing the in vitro activity of antimicrobial agents against rapidly growing aerobic bacteria involved in infectious diseases

CLSI M100, Performance Standards for Antimicrobial Susceptibility Testing; Informational Supplement

3 Terms and definitions

For the purposes of this document, the following terms and definitions apply.

3.1

antimicrobial agent

substance of biological, semi-synthetic or synthetic origin that inhibits the growth of or kills bacteria and is thus of potential use in the treatment of infections

Note 1 to entry: Disinfectants, antiseptics and preservatives are not included in this definition.

[SOURCE: ISO 20776-1:2006, 2.1]

3.2

antimicrobial disc

small paper disc containing known amounts of antimicrobial agents used for *in vitro* susceptibility testing

PD ISO/TS 16782:2016

ISO/TS 16782:2016(E)

3.3

concentration

amount of an antimicrobial agent in a defined volume of liquid

Note 1 to entry: The concentration is expressed as mg/l.

Note 2 to entry: $mg/l = \mu g/ml$ but it is not recommended to use the unit $\mu g/ml$.

[SOURCE: ISO 20776-1:2006, 2.2.2]

3.4

stock solution

initial solution used for further dilutions

[SOURCE: ISO 20776-1:2006, 2.3]

3.5

minimum inhibitory concentration

MIC

lowest concentration of antimicrobial agent that, under defined *in vitro* conditions, prevents visible growth of bacteria within a defined period of time

Note 1 to entry: The MIC is expressed in mg/l.

[SOURCE: ISO 20776-1:2006, 2.4, modified — "lowest concentration that" has been modified to "lowest concentration of antimicrobial agent that"]

3.6

reference strain

catalogued, characterized microorganism with stable, defined antimicrobial susceptibility phenotype and/or genotype

Note 1 to entry: Reference strains are kept as stock cultures, from which working cultures are derived. They are obtained from recognized national culture collections and used for quality control.

[SOURCE: ISO 20776-1:2006, 2.7, modified — "characterized bacteria" has been modified to "characterized microorganism" and "culture collections" in Note 1 to entry has been modified to "recognized national culture collections"]

3.7 Susceptibility testing method

3.7.1

broth dilution

technique in which containers are filled with appropriate volumes of broth containing an antimicrobial agent in incrementally (usually two-fold) increasing concentrations and a defined inoculum

Note 1 to entry: The aim of this method is the determination of the MIC.

[SOURCE: ISO 20776-1:2006, 2.8.1, modified — "an antimicrobial solution, employing incrementally (usually two-fold) increasing concentrations of the antimicrobial agent and appropriate volumes of broth with" has been modified to "broth containing an antimicrobial agent in incrementally (usually two-fold) increasing concentrations and"]

3.7.2

microdilution

performance of broth dilution in microdilution trays with a capacity of 200 µl per well

[SOURCE: ISO 20776-1:2006, 2.8.2, modified — "a capacity of ≤200 µl per well" has been modified to "a capacity of 200 µl per well"]

3.7.3

disc diffusion

technique in which antimicrobial discs are applied to the surface of an agar medium that has been evenly inoculated with a defined inoculum and, following incubation under defined conditions, the resulting size of zones of growth inhibition of the microorganism corresponds to the susceptibility/resistance of the microorganism to the antimicrobial agent

3.7.4

zone diameter

diameter (in mm) of the zone of growth inhibition around a paper disc containing an antimicrobial agent of specified amount used in a disc diffusion test

3.8

broth

liquid medium used for the *in vitro* growth of bacteria

[SOURCE: ISO 20776-1:2006, 2.9, modified — "fluid medium" has been modified to "liquid medium"]

3.9

inoculum

number of viable bacteria in a suspension, calculated with respect to the final volume

Note 1 to entry: The inoculum is expressed as colony-forming units per millilitre (CFU/ml).

[SOURCE: ISO 20776-1:2006, 2.10, modified — "number of bacteria" has been modified to "number of viable bacteria"]

3.10

dehydrated Mueller-Hinton broth

dMHB

dried bacteriological medium which is used to prepare liquid medium for broth dilution antimicrobial susceptibility tests

3.11

dehydrated Mueller-Hinton agar

dMHA

dried bacteriological medium which is used to prepare antimicrobial susceptibility testing agar plates for disc diffusion, gradient diffusion MIC and agar dilution MIC methods

4 Requirements for Mueller-Hinton broth

4.1 Components of Mueller-Hinton broth

Historically, Mueller-Hinton broth medium for antimicrobial susceptibility testing contains approximately the following components per litre of purified water (adjustments may be needed to meet performance criteria)[7]:

- dehydrated infusion from 300 g beef (i.e. 2 g of beef extract powder);
- acid digest of casein 17.5 g;
- starch 1,5 g.

4.2 Physical and chemical characteristics

4.2.1 Dehydrated powder or granules

Colour: beige to light beige.

Uniform, free-flowing, homogeneous and free of extraneous material.

4.2.2 Prepared broth medium

Once hydrated, the final pH measured after autoclaving shall be 7,2 to 7,4 at 25 °C.

The liquid is light straw coloured and clear with no visible precipitate.

4.2.3 Cation supplementation and content for MHB

The broth shall contain sufficient concentrations of cations to provide adequate growth and to permit the user to determine MIC values (e.g. aminoglycosides and quinolones) for quality control strains within ranges identified in ISO 20776-1:2006, Table 4 (check the latest version of CLSI and EUCAST documents for QC ranges). New lots of MHB may require testing for acceptable cation content. For standard production lots of dMHB, the broth prepared from the dehydrated product shall contain no greater than 25 mg/l of total calcium and 12,5 mg/l of total magnesium. Manufacturers may choose to provide commercial lots of dMHB with required concentrations of cations or actual levels less than 20 mg/l of calcium and 10 mg/l of magnesium. In the latter case, the final label shall specify the actual amounts contained in the lot of broth. For final testing, the prepared MHB shall contain 20 mg/l to 25 mg/l of Ca^{2+} and 10 mg/l to 12,5 mg/l of Mg^{2+} .

While trace amounts of manganese are required for growth, the concentration shall be below 8 mg/l to avoid false resistant interpretations with glycylcyclines[8]. This shall be determined by an MIC value within the acceptable range obtained by testing *Escherichia coli* WDCM 00013 with tigecycline.

While trace amounts of zinc are required for growth, the concentration of zinc shall be below 3 mg/l to avoid false resistance interpretations with imipenem^[9] and potentially with other carbapenems. This shall be determined by an MIC value within the acceptable range obtained by testing *Pseudomonas aeruginosa* WDCM 00025 with imipenem.

Cation concentrations of calcium, magnesium, manganese, and zinc shall be determined by inductively coupled plasma mass spectrometry (ICP-MS) or flame atomic absorption spectroscopy (FAAS)[10].

Although ion effects known to affect susceptibility test results for other antimicrobial agents are not included in this Technical Specification, they shall be considered for MHB dilution susceptibility tests by manufacturers at their discretion. Affected agents include daptomycin^[11] and polymyxin^[12]. When testing daptomycin, MHB shall be supplemented to a final concentration of 50 mg/l total Ca^{2+} . Refer to ISO 20776-1 for appropriate instructions on preparation of media and antimicrobial susceptibility testing.

4.2.4 Other medium components

The medium shall have a thymidine mass concentration of less than 0,03 mg/l as indicated by an MIC value of $\leq 0.5/9.5$ mg/l obtained by testing *Enterococcus faecalis* WDCM 00087 with trimethoprim-sulfamethoxazole^[13].

4.2.5 Specific adjustments required by the manufacturer

For antimicrobial agents included in <u>Table 1</u>:

- a) incorporation of sodium chloride (2 % *m/V* NaCl) at a final concentration of 20 g/l in the broth is required for the detection of methicillin resistance in *Staphylococcus* spp. when testing with oxacillin:
- b) for broth microdilution testing of tigecycline, when MIC panels are prepared, the medium shall be prepared fresh on the day of use. The medium shall be no more than 12 h old at the time the panels are made; however, the panels may then be frozen for later use. For further details, refer to ISO 20776-1.

Manufacturers may choose to test additional antimicrobial agents and strains, as well as Mueller-Hinton media supplemented for growth of fastidious strains. The expected performance limits shall be validated.

For organisms not included in <u>Table 1</u> (i.e. for extended testing at the discretion of the manufacturer):

c) testing of fastidious organisms such as streptococci and *Haemophilus* spp. requires the addition of growth supplements (for example, blood or blood components). If a Mueller-Hinton agar or broth lot that is found to perform acceptably according to the criteria in this Technical Specification is to be used for testing fastidious organisms, the resulting MICs or zone diameters after addition of supplements shall fall within the acceptable quality control ranges published in 20776-1 for the specific medium and organism tested.

See A.1 for a summary of specific effects on antimicrobial agents.

4.3 Manufacturers protocol for testing production lots of dehydrated Mueller-Hinton broth

Procedures for preparing microdilution trays and performing the test are described in ISO 20776-1. Those procedures shall be followed with restrictions noted below.

- a) The minimum and maximum concentration of each antimicrobial agent on each tray shall bracket the quality control limit range by at least two doubling dilutions beyond each limit.
- b) As a minimum, test a single microbial inoculum in three separate trays for each of the microorganism-antimicrobial combinations listed in 4.4. This list of microorganism-antimicrobial agent combinations represents the minimum requirements for testing and includes agents likely to detect particular problems with the medium. Other antimicrobial agents may be tested at the manufacturer's discretion as needed to ensure consistent performance of the medium. The medium shall be appropriate for the antimicrobial agents tested.
- c) See ISO 20776-1, CLSI or EUCAST or EUCAST or specific details of quality control strain maintenance. At least two days before testing, thaw a vial of each of the control cultures that will be needed (see 4.4). Inoculate each culture onto a plate of non-selective nutritive agar medium and incubate it for 18 h to 24 h at 34 °C to 37 °C in ambient air as described in ISO 20776-1. After incubation, check for purity. The day before the inoculation of the test plates, subculture again to provide fresh colonies for inoculum preparation. All microorganisms shall be subcultured at least twice from the frozen state before being used for testing.
- d) If frozen trays are used, they shall be allowed to thaw completely at ambient room temperature (usually takes 1 h to 2 h) before use. Trays shall be used on the same day that they are thawed.
- e) Tests shall be set up as described in ISO 20776-1. A single inoculum for each quality control strain shall be prepared using the colony suspension method. Inoculated microdilution trays should be incubated for 16 h to 20 h (24 h for oxacillin with *Staphylococcus aureus*) and read within one hour of removal from the incubator.
- f) Results shall be recorded and maintained according to the manufacturer's policies for record retention. A suggested data sheet for this purpose is shown in Annex C.

4.4 Interpreting the results

The acceptable MIC ranges in <u>Table 1</u> were obtained with permission from CLSI^[14] and EUCAST [http://www.eucast.org/ast_of_bacteria/qc_tables/]^[15].

The acceptable ranges are subject to revision. Therefore the latest version of Reference [14] or the EUCAST Tables shall be checked for possible updates.

See <u>Annex B</u> for alternative numbers for the same control microorganism from different culture collections.

Table 1 — MIC ranges (mg/l) for control strains

Quality control strain	Antimicrobial agent	Acceptable range
		mg/l
	Ciprofloxacin	0,25-1
Pseudomonas aeruginosa	Gentamicin	0,5-2
WDCM 00025	Imipenem	1–4
	Piperacillin-tazobactam	1/4-8/4
Escherichia coli	Ampicillin	2-8
	Cefotaxime	0,03-0,12
WDCM 00013	Tigecycline	0,03-0,25
	Clindamycin	0,06-0,25
Ctanbula an agua guraya	Erythromycin	0,25-1
Staphylococcus aureus	Oxacillin	0,12-0,5
WDCM 00131	Tetracycline	0,12-1
	Vancomycin	0,5-2
Entanaga gaya fa agalia	Ampicillin	0,5-2
Enterococcus faecalis	Trimethoprim- sulfamethoxazole	≤0,5/9,5ª
WDCM 00087	Vancomycin	1-4
Staphylococcus aureus WDCM 00211	Oxacillin	4-32

^a CLSI or EUCAST has not yet established a control range for trimethoprim-sulfamethoxazole. The MIC results for trimethoprim-sulfamethoxazole shall be </=0.5/9.5 mg/l.

4.5 Evaluating the results

If all performance criteria for all microorganism-antimicrobial agent combinations are within acceptable ranges listed in $\underline{4.4}$ and all physical and chemical characteristics are met (see $\underline{4.2}$), the manufacturer may apply the label statement given in $\underline{\text{Annex D}}$. Manufacturers should attempt to achieve mean MIC values close to the midpoint of the control ranges. Data shall be maintained on file and results made available to anyone upon request.

5 Requirements for Muller-Hinton agar

5.1 Components of Mueller-Hinton agar

Historically, Mueller-Hinton agar medium for antimicrobial susceptibility testing contains approximately (adjustment may be needed to meet performance criteria) the following components per litre of purified water^[Z]:

- dehydrated infusion from 300 g beef (i.e. 2 g of beef extract powder);
- acid digest of casein 17,5 g;
- starch 1,5 g;
- agar 17 g.

5.2 Physical and chemical characteristics

5.2.1 Dehydrated powder or granules

Colour: beige to light beige.

Uniform, free-flowing, homogeneous and free of extraneous material.

5.2.2 Prepared agar medium

The final pH measured after autoclaving and gelling shall be 7,2 to 7,4 at 25 °C.

The gelled medium is light straw coloured and slightly opalescent. The depth of medium in the plate shall be uniform and within the range of 3,5 mm to 5,0 mm [EUCAST specifies 4 mm \pm 0,5 mm and CLSI either approximately 4 mm[6] or 4 mm to 5 mm (CLSI document M6[1])]. Plates from different sources might differ in diameter (measured internally at the base of the plate) and the agar volume required to provide the specified depth is calculated from the formula "3,143 \times plate radius (cm) squared \times depth (cm)". Hence, the acceptable range of depth of the medium for 90 mm, 100 mm and 150 mm internal diameter round plates is achieved with volumes of 23 ml to 31 ml, 28 ml to 39 ml, and 62 ml to 88 ml, respectively. For other plate sizes, the volume of medium required shall be calculated.

5.2.3 Cation supplementation and content for MHA

The agar shall contain sufficient concentrations of cations to provide adequate growth and to permit the user to determine zone diameters for quality control strains within ranges identified in <u>5.4</u>.

The medium shall have Ca²⁺ and Mg²⁺ cation concentrations such as to provide zone diameter values within expected range for *Pseudomonas aeruginosa* vs aminoglycoside class of antimicrobial agents as shown by zone diameter with gentamicin and *Pseudomonas aeruginosa* WDCM 00025 within the acceptable range.

While trace amounts of manganese are required for growth, the concentration shall be below 8 mg/l to avoid false resistant interpretations with glycylcyclines^[8]. This shall be determined by a value within the acceptable range obtained by testing *Escherichia coli* WDCM 00013 with tigecycline.

To avoid false resistant interpretations when testing carbapenems, the medium shall have a zinc concentration below 3 mg/l, as shown by zone diameter with imipenem and *Pseudomonas aeruginosa* WDCM 00025 within the acceptable range. The effect of excess zinc concentration is known to be true for imipenem and may apply to other carbapenems.

5.2.4 Other medium components

The medium shall have a thymidine mass concentration of less than 0,03 mg/l as shown by the clarity and zone of inhibition with trimethoprim-sulfamethoxazole of \geq 20 mm for *Enterococcus faecalis* WDCM 00210 or by a zone diameter within the acceptable range obtained by testing *Enterococcus faecalis* WDCM 00087.

Consistent and adequate gel strength is required for reproducible zone sizes that meet quality control specifications.

5.2.5 Specific adjustments required by the manufacturer

Testing of fastidious organisms such as streptococci and *Haemophilus* spp. requires the addition of growth supplements (for example, blood or blood components). If a Mueller-Hinton agar or broth lot that is found to perform acceptably according to the criteria in this Technical Specification is to be used for testing fastidious organisms, the resulting MICs or zone diameters after addition of supplements shall fall within the acceptable quality control ranges published in CLSI^[5] or EUCAST^[3] documents for the specific medium and organism tested.

See A.2 for a summary of specific effects on antimicrobial agents. Organisms/antimicrobial agents not specified may be tested by the manufacturer at their discretion.

5.3 Manufacturer's protocol for testing production lots of dehydrated Mueller-Hinton agar

The disc diffusion method shall be used to evaluate production lots of dMHA. CLSI^[5] and EUCAST^[3] describe the procedures for preparing plates, performing and reading the test, and strain maintenance. Those procedures shall be followed with the restrictions noted below.

- a) As a minimum, test a single inoculum on three separate plates for each microorganism-antimicrobial agent combinations listed in <u>5.4</u>. This list of microorganism-antimicrobial agent combinations represents the minimum requirements for testing and includes agents likely to detect particular problems with the medium. Other antimicrobial agents may be tested at the manufacturer's discretion as needed to ensure consistent performance of the medium. The medium shall be appropriate for the antimicrobial agents to be tested.
- b) At least two days before the inoculation of the test plates, thaw a vial of each of the control cultures that will be needed (see below and Annex C). Inoculate each culture onto a plate of non-selective nutritive agar medium and incubate it for 18 h to 24 h at 35 °C ± 2 °C (CLSI) or 35 °C ± 1 °C (EUCAST) in ambient air. After incubation, check for purity. The day before the inoculation of the test plates, subculture should be repeated. All microorganisms shall be subcultured at least twice from the frozen state before being used for testing.
- c) A single inoculum for each quality control strain shall be prepared using the colony suspension method as described in the most recent version of CLSI or EUCAST documents.
- d) Inoculate the three replicate plates of each medium with the standardized inoculum of each of the control cultures. Inoculate plates within 15 min after adjusting the inoculum suspension.
- f) After incubation at the appropriate temperature [i.e. $35 \,^{\circ}\text{C} \pm 2 \,^{\circ}\text{C}$ (CLSI) or $35 \,^{\circ}\text{C} \pm 1 \,^{\circ}\text{C}$ (EUCAST)] and for the appropriate time (i.e. $16 \,^{\circ}\text{h}$ to $20 \,^{\circ}\text{h}$), remove plates from the incubator and read within one hour. For enterococci with vancomycin, incubation time shall be increased to $24 \,^{\circ}\text{h}$.
- g) Results shall be recorded and maintained according to the manufacturer's policies for record retention. A suggested data sheet for this purpose is shown in Annex C.

5.4 Interpreting the results

See <u>Annex B</u> for alternative numbers for the same control microorganism from different culture collections.

Table 2 — Disc diffusion ranges (in mm) for control strains

Quality control strain	Disc content	Antimicrobial agent	Acceptable range
	μg		mm
	20/10	Amoxicillin-clavulanate	28-36
	10/10	Ampicillin-sulbactam	29-37
	30	Cefoxitin	23-29
	5	Ciprofloxacin	22-30
Staphylococcus aureus WDCM 00034a	15	Erythromycin	22-30
W DGM 0003 I	10	Gentamicin	19-27
	30	Linezolid	25-32
	10 units	Penicillin	26-37
	30	Tetracycline	24-30
	1 unit	Penicillin (benzylpenicillin)	12-18
	30	Cefoxitin	24-30
Staphylococcus aureus —	5	Ciprofloxacin	21-27
	15	Erythromycin	23-29
WDCM 00131 ^{a,b}	10	Gentamicin	19-25
	10	Linezolid	21–27
	30	Tetracycline	23-31
	2	Ampicillin	15-21
	10	Imipenem	24-30
	10	Linezolid	19-25
Enterococcus faecalis	100	Nitrofurantoin	18-24
WDCM 00087c	5	Trimethoprim	24-32
	1,25-23,75	Trimethoprim-sulfamethox-azole	26-34
	5	Vancomycin	10-16

^a With *S. aureus* WDCM 00034, use linezolid 30 µg discs and penicillin 10 unit discs. With *S. aureus* WDCM 00131, use linezolid 10 µg discs and penicillin (benzylpenicillin) 1 unit discs.

b Disc diffusion ranges from EUCAST control range tables[3]. Check the latest version from EUCAST http://www.eucast.org for updated ranges as they are subject to periodic updates. *S. aureus* WDCM 00131 is an alternative quality control microorganism to *S. aureus* WDCM 00034 for disc diffusion testing for the antimicrobial agents in common. *S. aureus* WDCM 00034 shall be tested with antimicrobial agents for which no acceptable range for WDCM 00131 is available. Cefoxitin is replacing oxacillin as the surrogate for detection of methicillin-resistant *Staphylococcus aureus* (MRSA). Oxacillin disc diffusion testing is no longer recommended. Refer to CLSI[5] or EUCAST[3] documents.

c The zone of inhibition for trimethoprim-sulfamethoxazole shall be ≥20 mm.

d The zone of inhibition for cefoxitin (CLSI[3]) shall be ≤21 mm.

Table 2 (continued)

Quality control strain	Disc content	Antimicrobial agent	Acceptable range
	μg		mm
	20/10	Amoxicillin-clavulanate	18-24
	10	Ampicillin	15-22
	30 or	Cafabanina	29-35
	5	Cefotaxime	25-31
	30	Chloramphenicol	21-27
Escherichia coli	5	Ciprofloxacin	30-40
WDCM 00013	10	Gentamicin	19-26
	250 or 300	Sulfisoxazole	15-23
	30	Tetracycline	18-25
	15	Tigecycline	20-27
	1,25/23,75	Trimethoprim-sulfamethox-azole	23-29
	30	Aztreonam	23-29
	10 or	Ceftazidime	21–27
	30	Certazidinie	22-29
	5	Ciprofloxacin	25-33
Pseudomonas aeruginosa WDCM 00025	10	Gentamicin	17-23
W DGM 00023	10	Imipenem	20-28
	100/10 or	Din ana sillin tanah satam	25-33
	30/6	Piperacillin-tazobactam	23-29
	10	Tobramycin	20-26
Enterococcus faecalis WDCM 00210	1,25/23,75	Trimethoprim-sulfamethox-azole	С
Staphylococcus aureus WDCM 00211	30	Cefoxitin	d
Staphylococcus aureus WDCM 00212	30	Cefoxitin	14-20

^a With *S. aureus* WDCM 00034, use linezolid 30 µg discs and penicillin 10 unit discs. With *S. aureus* WDCM 00131, use linezolid 10 µg discs and penicillin (benzylpenicillin) 1 unit discs.

5.5 Evaluating the results

If all performance criteria for all microorganism-antimicrobial agent combinations are within acceptable limits (see 5.4) and all physical and chemical characteristics are met (see 5.2), the manufacturer may apply the label statement specified in Annex D. Manufacturers should attempt to achieve mean zone diameter values close to the midpoint of the control ranges. Data shall be maintained on file and results made available to anyone upon request.

b Disc diffusion ranges from EUCAST control range tables[3]. Check the latest version from EUCAST http://www.eucast.org for updated ranges as they are subject to periodic updates. *S. aureus* WDCM 00131 is an alternative quality control microorganism to *S. aureus* WDCM 00034 for disc diffusion testing for the antimicrobial agents in common. *S. aureus* WDCM 00034 shall be tested with antimicrobial agents for which no acceptable range for WDCM 00131 is available. Cefoxitin is replacing oxacillin as the surrogate for detection of methicillin-resistant *Staphylococcus aureus* (MRSA). Oxacillin disc diffusion testing is no longer recommended. Refer to CLSI[5] or EUCAST[3] documents.

^c The zone of inhibition for trimethoprim-sulfamethoxazole shall be ≥20 mm.

d The zone of inhibition for cefoxitin (CLSI[3]) shall be ≤21 mm.

6 Testing new antimicrobial agents with production lots of dehydrated Mueller-Hinton broth or agar

When *in vitro* data on new antimicrobial agents are being developed, dMHB or dMHA production lots meeting the criteria in this Technical Specification shall be used to develop *in vitro* quality control parameters for these new antimicrobial agents. Testing of production lots of dMHB or dMHA with new antimicrobial agents shall follow the procedures outlined in this Technical Specification. For dMHB, ion content shall be examined to determine whether the new antimicrobial agent is affected by specific cations or anions or concentrations of ions in the medium that differ from the ranges suggested in this Technical Specification. Other medium components that could affect results of *in vitro* quality control susceptibility tests that come to light during these investigations shall be identified. Adjustments shall be made as necessary to achieve stable, reproducible test results, and this information shall be widely circulated to others involved in antimicrobial susceptibility testing and quality control including the CLSI Subcommittee on Antimicrobial Susceptibility Testing and EUCAST. This is the responsibility of the company manufacturing the new agent.

Annex A

(informative)

Mueller-Hinton medium

A.1 Broth

Table A.1 — Effects of dehydrated Mueller-Hinton broth

Antimicrobial	Remarks
Aminoglycosides	Specified levels of calcium (20 mg/l to 25 mg/l) and magnesium (10 mg/l to 12,5 mg/l) are based on studies[16][17] comparing Mueller-Hinton agar and broth dilution for clinical strains of <i>P. aeruginosa</i> .
Carbapenems	While trace amounts of zinc are required for growth, the concentration of zinc shall be below 3 mg/l to avoid false resistance interpretations ^[9] . This is known to be true for imipenem and may apply to other carbapenems.
Daptomycin	Medium shall be supplemented to a final concentration of 50 mg/l total Ca ²⁺ .
Folate pathway inhibitors (eg. Sulfonamides and Trimethoprim)	The medium shall have a thymidine mass concentration of less than 0,03 mg/l as indicated by a value of <0,5/9,5 mg/l obtained by testing <i>Enterococcus faecalis</i> WDCM 00087 with trimethoprim-sulfamethoxazole.
Fosfomycin	Only agar dilution shall be used as the reference method because broth dilution is not reliable[4][6].
Glycylcylines (eg. Tigecycline)	Freshly prepared (<12 h) test medium shall be used. This may also apply to other antimicrobial agents in this drug class.
	While trace amounts of manganese are required for growth, the concentration shall be below 8 mg/l to avoid false resistant interpretations[8]. This shall be determined by a value within the acceptable MIC range obtained by testing <i>Escherichia coli</i> WDCM 00013 with tigecycline.
Lipoglycopeptides (eg. Dalbavancin and Or- itavancin)	The broth shall be supplemented with 0,002 % v/v polysorbate-80. This may also apply to other members of this drug class.
Oxacillin	Incorporation of NaCl at a final concentration of 20 g/l in the broth is required for the detection of methicillin resistance in <i>Staphylococcus</i> spp. when testing with oxacillin.
Quinolones	Data from studies of quinolone activity in human urine suggest that decreased quinolone activity may occur when magnesium concentrations are 8 mm to 10 mm (100 mg/l to 150 mg/l) in Mueller-Hinton medium[18]. Other data indicate that 35 mg/l to 60 mg/l of magnesium cause an increase in MICs for several species of bacteria[19][20].
Tetracyclines	Mueller-Hinton broth supplemented to contain 50 mg/l of calcium and 25 mg/l of magnesium has been shown to increase MICs for <i>E. coli, P. aeruginosa,</i> and other species of <i>Pseudomonas</i> by 2- to 32- fold[12].
All	Testing of fastidious microorganisms such as streptococci and <i>Haemophilus</i> spp. requires the addition of growth supplements (for example, blood or blood components)[4][6].

A.2 Agar

 ${\bf Table~A.2-Effects~of~dehydrated~Mueller-Hinton~agar}$

Antimicrobial	Remarks
Aminoglycosides	The medium shall have Ca ²⁺ and Mg ²⁺ concentrations such as to provide zone diameter values within expected range for <i>Pseudomonas aeruginosa</i> vs the aminoglycoside class of antimicrobial agents as shown by zone diameter with gentamicin and <i>Pseudomonas aeruginosa</i> WDCM 00025 within the acceptable range.
Carbapenems	While trace amounts of zinc are required for growth, the concentration of zinc shall be below 3 mg/l to avoid false resistance interpretations[9]. This is known to be true for imipenem and may apply to other carbapenems.
Daptomycin	Cannot be tested by disc diffusion
Folate pathway inhibitors (eg. Sulfonamides and Trimethoprim)	The medium shall have a thymidine mass concentration of less than 0,03 mg/l as shown by the clarity and zone of inhibition with trimethoprim-sulfamethoxazole of \geq 20 mm for <i>E. faecalis</i> WDCM 00210 or by a zone diameter within the acceptable range obtained using <i>E. faecalis</i> WDCM 00087.
Fosfomycin	Only agar dilution shall be used as the reference method because broth dilution is not reliable [4][6]. The test agar shall be supplemented with 25 mg/l glucose-6-phosphate.
Glycylcyclines (eg. Tigecycline)	Freshly prepared (<12 h) test medium shall be used. This may also apply to other antimicrobial agents in this drug class.
	While trace amounts of manganese are required for growth, the concentration shall be below 8 mg/l to avoid false resistant interpretations[8]. This shall be determined by a value within the acceptable range obtained by testing <i>Escherichia coli</i> WDCM 00013 with tigecycline.
Quinolones	Data indicate that 35 mg/l to 60 mg/l of magnesium cause a reduction in zone diameters and an increase in MICs for several species of bacteria ^[19] [20].
Tetracyclines	The medium shall have calcium and magnesium concentrations such as to provide zone diameter values within expected range for <i>Pseudomonas aeruginosa</i> vs aminoglycoside class of antimicrobial agents as shown by zone diameter with gentamicin and <i>Pseudomonas aeruginosa</i> WDCM 00025 within the acceptable range.
All	Testing of fastidious microorganisms such as streptococci and <i>Haemophilus</i> spp. requires the addition of growth supplements (e.g. blood or blood components)[3][5].

Annex B

(informative)

Preparing control cultures

B.1 Stock cultures

Stock cultures are prepared from lyophilized cultures obtained from a recognized national culture collection. Cultures shall be reconstituted according to procedures defined by the culture collection and maintained in such a way that selection of genetic variants is minimized. Alternative numbers for the same microorganism from different culture collections are listed below when available. The following are the cultures required for the purposes of this protocol:

Staphylococcus aureus	WDCMa 00131; ATCC®b 29213; NCTC®c 12973; CIPd 103429; DSMe 2569; CCUGf 15915; CECTg 794
Staphylococcus aureus	WDCM ^a 00034; ATCC ^{®b} 25923; NCTC ^{®c} 12981; CIP ^d 76.25; DSM ^e 1104; CCUG ^f 17621; CECTg 435
Staphylococcus aureus	WDCMa 00211; ATCC®b 43300
or	
Staphylococcus aureus	WDCMa 00212; NCTC®c 12493
Escherichia coli	WDCMa 00013; ATCC®b 25922; NCTC®c 12241; CIPd 76.24; DSMe 1103; CCUGf 17620; CECTg 434
Pseudomonas aeruginosa	WDCMa 00025; ATCC®b 27853; NCTC®c 12903; CIPd 76.110; DSMe 1117; CCUGf 17619; CECTg 108
Enterococcus faecalis	WDCM ^a 00087; ATCC ^{®b} 29212; NCTC ^{®c} 12697; CIP ^d 103214; DSM ^e 2570; CCUG ^f 9997; CECT ^g 795
or	
Enterococcus faecalis	WDCMa 00210; ATCC®b 33186

a WDCM, World Data Centre for Microorganisms, www.wdcm.org.

- d CIP, Collection de l'Institut Pasteur, <u>www.pasteur.fr</u>.
- e DSMZ, Deutsche Stammsammlung für Mikroorganismen und Zellkulturen, www.dsmz.de.
- f CCUG, Culture Collection, University of Göteborg, www.ccug.se.
- GECT, Colección Española de Cultivos Tipo, www.cect.org.

B.1.1 Preparing the initial stock cultures

Using a sterile loop or swab, inoculate one or more plates (depending on the number of frozen replicate vials that are to be prepared) of non-selective nutritive agar with each control microorganism listed in B.1. Streak each plate to obtain isolated colonies. Incubate the plates for 18 h to 24 h as per ISO 20776-1 at 34 °C to 37 °C in ambient air.

b ATCC is the trademark of a product supplied by American Type Culture Collection, www.atcc.org. This information is given for the convenience of users of this Technical Specification and does not constitute an endorsement by ISO of the product named. Equivalent products can be used as listed above.

Collection of Type Cultures, a culture collection of Public Health England, www.hpacultures.org.uk. This information is given for the convenience of users of this Technical Specification and does not constitute an endorsement by ISO of the product named. Equivalent products can be used as listed above.

B.1.2 Preparing frozen stock cultures

After incubation, check for purity and harvest the entire growth from each set of plates and emulsify it in soybean-casein digest broth [tryptic soy broth (TSB)] containing 15 % w/v glycerol to prepare a uniformly dense suspension. Store the vials at -60 °C or a lower temperature. With this method, cultures shall be viable for at least one year. Other methods of preparing stock cultures may be used if they provide adequate viability and stability. Periodically renew stock cultures from fresh lyophilized cultures obtained from recognized culture collections.

NOTE To prepare the TSB with glycerol, add the manufacturer's recommended amount of TSB powder or granule for preparing one litre, then add 500 ml of deionized water and 150 ml of glycerol. Adjust the final total volume to 1 l with deionized water, heat to dissolve and mix well, and sterilize it at 121 $^{\circ}$ C for 15 min. Dispense the suspension into small, sterile vials.

B.1.3 Preparing the stock culture test inoculum

Refer to 4.3 for preparing test inoculum.

Annex C (informative)

Suggested data sheet for testing of production lots

C.1 Suggested data sheet for testing of production lots of dMHB

Date:	
Production lot number:	
Batch size:	
Description of colour:	
Clarity:	

Antimicrobial agent	Acceptable range	MIC mg/l			
	mg/l	1	2	3	
P. aeruginosa WDCM 00025					
Ciprofloxacin	0,25-1				
Gentamicin	0,5-2				
Imipenem	1-4				
Piperacillin-tazobactam	1/4-8/4				
E. coli WDCM 00013					
Ampicillin	2-8				
Cefotaxime	0,03-0,12				
Tigecycline	0,03-0,25				
S. aureus WDCM 00131					
Clindamycin	0,06-0,25				
Erythromycin	0,25-1				
Oxacillin	0,12-0,5				
Tetracycline	0,12-1				
Vancomycin	0,5-2				
E. faecalis WDCM 00087					
Ampicillin	0,5-2				
Trimethoprim-sulfamethoxazole	≤0,5/9,5				
Vancomycin	1-4				
S. aureus WDCM 00211					
Oxacillin	4-32				

Ranges are subject to periodic updates. Check the latest version of M100 available from CLSI for updated ranges. CLSI, 950 West Valley Road, Suite 2500, Wayne, PA 19087, USA^[14] or check the latest version of EUCAST QC tables available from EUCAST at http://www.eucast.org/ast_of_bacteria/qc_tables/.

pH:

C.2 Suggested data sheet for testing of production lots of dMHA

\mathbf{r}	_	_	_	
	а	т	ப	۰
$\mathbf{\nu}$	а	u	u	

Production lot number:

Batch size:

Description of colour:

Clarity:

Gel strength:

рН:

Antimicrobial agent	Disc content μg	Acceptable range	Zone diameter, nearest whole mm		
		******	1 2		3
S. aureus WDCM 00034					
Amoxicillin-clavulanate	20/10	28-36			
Ampicillin-sulbactam	10/10	29-37			
Cefoxitin	30	23-29			
Ciprofloxacin	5	22-30			
Erythromycin	15	22-30			
Gentamicin	10	19-27			
Linezolid	30	25-32			
Penicillin	10 units	26-37			
Tetracycline	30	24-30			
S. aureus WDCM 00131					
Penicillin (benzylpenicillin)	1 unit	12-18			
Cefoxitin	30	24-30			
Ciprofloxacin	5	21-27			
Erythromycin	15	23-29			
Gentamicin	10	19-25			
Linezolid	10	21-27			
Tetracycline	30	23-31			
E. faecalis WDCM 00087					
Ampicillin	2	15-21			
Imipenem	10	24-30			
Linezolid	10	19-25			
Nitrofurantoin	100	18-24			
Trimethoprim	5	24-32			
Trimethoprim-sulfamethoxazole	1,25-23,75	26-34			
Vancomycin	5	10-16			
E. coli WDCM 00013					
Amoxicillin-clavulanate	20/10	18-24			
Ampicillin	10	15-22			
	30 or	29-35			
Cefotaxime	5	25-31			

Antimicrobial agent	Disc content μg	Acceptable range	Zone diameter, nearest whole			
		mm	mm			
			1	2	3	
Chloramphenicol	30	21-27				
Ciprofloxacin	5	30-40				
Gentamicin	10	19-26				
Sulfisoxazole	250 or 300	15-23				
Tetracycline	30	18-25				
Tigecycline	15	20-27				
Trimethoprim-sulfamethoxazole	1,25/23,75	23-29				
P. aeruginosa WDCM 00025						
Aztreonam	30	23-29				
C (1 1)	10 or	21-27				
Ceftazidime	30	22-29				
Ciprofloxacin	5	25-33				
Gentamicin	10	17-23				
Imipenem	10	20-28				
Di dili di la di l	100/10 or	25-33				
Piperacillin-tazobactam	30/6	23-29				
Tobramycin	10	20-26				
E. faecalis WDCM 00210						
Trimethoprim-sulfamethoxazole	1,25/23,75	≥20				
S. aureus WDCM 00211						
Cefoxitin	30	≤21				
S. aureus WDCM 00212						
Cefoxitin	30	14-29				

Ranges are subject to periodic updates. Check the latest version of M100 available from CLSI for updated ranges. CLSI, 950 West Valley Road, Suite 2500, Wayne, PA 19087, USA $^{[14]}$ or check the latest version of EUCAST QC tables available from EUCAST at http://www.eucast.org/ast_of_bacteria/qc_tables/.

Annex D (informative)

Label statement

D.1 Dehydrated Mueller-Hinton broth

If all performance criteria for all microorganism-antimicrobial agent combinations are within acceptable limits and all physical and chemical characteristics are met, the manufacturer may indicate for that production lot that the dMHB (lot number) conforms to the performance criteria laid out in ISO 16782 for antimicrobial susceptibility testing. For standard production lots of dMHB, the broth prepared from the dehydrated product shall contain no greater than 25 mg/l of Ca^{2+} , 12,5 mg/l of Mg^{2+} , and shall have less than 3 mg/l of zinc ions. A certificate of analysis shall be available to the user of dMHB that specifies the concentrations of these ions in the lot of dehydrated medium and indicates if additional calcium and/or magnesium is required to achieve the concentrations specified in ISO 20776-1.

D.2 Dehydrated Mueller-Hinton agar

If all performance criteria for all microorganism-antimicrobial agent combinations are within acceptable limits and all physical and chemical characteristics are met, the manufacturer may indicate for that production lot that the dMHA (lot number) conforms to the performance criteria laid out in ISO 16782 for antimicrobial susceptibility testing.

D.3 Label statement

For acceptable lots, the following statement may be added to the product label or instructions for use:

"This lot of dehydrated Mueller-Hinton agar/broth has been tested according to ISO 16782 and meets quality control criteria as stated in ISO 16782."

Data shall be maintained on file and results made available to anyone upon request.

Bibliography

- [1] NCCLS. Evaluation of Lots of Dehydrated Mueller-Hinton Broth for Antimicrobial Susceptibility Testing; Proposed Guideline. NCCLS document M32-P. Wayne, PA: NCCLS; 2001¹⁾
- [2] CLSI. *Protocols for Evaluating Dehydrated Mueller-Hinton Agar*; Approved Standard—Second edition. CLSI document M6-A2. Wayne, PA: Clinical and Laboratory Standards Institute; 2006¹)
- [3] EUROPEAN COMMITTEE ON ANTIMICROBIAL SUSCEPTIBILITY TESTING. 2012), Disk diffusion method. (for latest version, see http://www.eucast.org/ast_of_bacteria/disk_diffusion_methodology)
- [4] EUROPEAN COMMITTEE ON ANTIMICROBIAL SUSCEPTIBILITY TESTING. Determination of minimum inhibitory concentrations (MICs) of antibacterial agents by agar dilution, EUCAST Definitive Document E.Def 3.1. 2000, **9** pp. 509-515
- [5] CLSI. Performance Standards for Antimicrobial Disk Susceptibility Tests; Approved Standard— Twelfth Edition. CLSI document M02-A12. Wayne, PA: Clinical and Laboratory Standards Institute; 2015
- [6] CLSI. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically; Approved Standard—Tenth Edition. CLSI document M07-A10. Wayne, PA: Clinical and Laboratory Standards Institute; 2015
- [7] MUELLER J.H., & HINTON J. A protein-free medium for primary isolation of the gonococcus and meningococcus. Proc. Soc. Exp. Biol. Med. 1941, **48** p. 330
- [8] VEENEMANS J., MOUTON J.W., KLUYTMANS J.A.J.W., DONNELY R. Verhulst, C., van Keulen, PHJ. *Effect of manganese in test media on in vitro susceptibility of Enterobacteriaceae and Acinetobacter baumannii to tigecycline.* J. Clin. Microbiol. 2012, **50** pp. 3077–3079
- [9] DALY J.S., DODGE R.A., GLEW R.H., SOJA D.T., DELUCA B.A., HEBERT S. Effect of zinc concentration in Mueller-Hinton agar on susceptibility of Pseudomonas aeruginosa to imipenem. J. Clin. Microbiol. 1997, **35** pp. 1027–1029
- [10] MORRISON G.H. *Critical Reviews in Analytical Chemistry.* 1969;(14):28A. ©CRC Press, Boca Raton, Florida
- [11] FUCHS P.C., BARRY A.L., BROWN S.D. Daptomycin susceptibility tests: interpretive criteria, quality control, and effect of calcium on in vitro tests. Diagn. Microbiol. Infect. Dis. 2000, **38** pp. 51–58
- [12] FASS R.J., & BARNISHAN J. Effect of divalent cation concentrations on the antibiotic susceptibilities of non-fermenters other than Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 1979, **16** pp. 434–438
- [13] SWENSON J.M., & THORNSBERRY C. Susceptibility Tests for Sulfamethoxazole-Trimethoprim by a Broth Microdilution Procedure. Curr. Microbiol. 1978, 1 pp. 89–193
- [14] CLSI. Performance Standards for Antimicrobial Susceptibility Testing. 26th ed. CLSI M100S. Wayne, PA: CLINICAL AND LABORATORY STANDARDS INSTITUTE; 2016.
- [15] The European Committee on Antimicrobial Susceptibility Testing. Routine and extended internal quality control for MIC determination and disk diffusion as recommended by EUCAST. Version 6.0, 2016. http://www.eucast.org."

¹⁾ Upon publication of ISO 16782, CLSI document M6-A2 and M32-P will be discontinued and no longer available.

- [16] BARRY A.L., MILLER G.H., THORNSBERRY C. Influence of cation supplements on activity of netilmicin against Pseudomonas aeruginosa in vitro and in vivo. Antimicrob. Agents Chemother. 1987, **31** pp. 1514–1518
- [17] Barry A.L., Reller L.B., Miller G.H. Revision of standards for adjusting the cation content of Mueller-Hinton broth for testing susceptibility of Pseudomonas aeruginosa to aminoglycosides. J. Clin. Microbiol. 1992, **30** pp. 585–589
- [18] ELIOPOULOS G.M., & ELIOPOULOS C.T. *Quinolone antimicrobial agents: Activity in vitro. In Wolfson JS, Hooper DC, eds. Quinolone Antimicrobial Agents.* Washington, D.C.: American Society for Microbiology; 1989:3:35-70
- [19] AUCKENTHALER R., MICHEA-HAMZEHPOUR M., PECHERE J.C. In vitro activity of newer quinolones against aerobic bacteria. J. Antimicrob. Chemother. 1986, 17 () pp. 29–39
- [20] BLASER J., DUDLEY M.N., GILBERT D., ZINNER S.H. Influence of medium and method on the in vitro susceptibility of Pseudomonas aeruginosa and other bacteria to ciprofloxacin and enoxacin. Antimicrob. Agents Chemother. 1986, **29** pp. 927–929



British Standards Institution (BSI)

BSI is the national body responsible for preparing British Standards and other standards-related publications, information and services.

BSI is incorporated by Royal Charter. British Standards and other standardization products are published by BSI Standards Limited.

About us

We bring together business, industry, government, consumers, innovators and others to shape their combined experience and expertise into standards -based solutions.

The knowledge embodied in our standards has been carefully assembled in a dependable format and refined through our open consultation process. Organizations of all sizes and across all sectors choose standards to help them achieve their goals.

Information on standards

We can provide you with the knowledge that your organization needs to succeed. Find out more about British Standards by visiting our website at bsigroup.com/standards or contacting our Customer Services team or Knowledge Centre.

Buying standards

You can buy and download PDF versions of BSI publications, including British and adopted European and international standards, through our website at bsigroup.com/shop, where hard copies can also be purchased.

If you need international and foreign standards from other Standards Development Organizations, hard copies can be ordered from our Customer Services team.

Copyright in BSI publications

All the content in BSI publications, including British Standards, is the property of and copyrighted by BSI or some person or entity that owns copyright in the information used (such as the international standardization bodies) and has formally licensed such information to BSI for commercial publication and use.

Save for the provisions below, you may not transfer, share or disseminate any portion of the standard to any other person. You may not adapt, distribute, commercially exploit, or publicly display the standard or any portion thereof in any manner whatsoever without BSI's prior written consent.

Storing and using standards

Standards purchased in soft copy format:

- A British Standard purchased in soft copy format is licensed to a sole named user for personal or internal company use only.
- The standard may be stored on more than 1 device provided that it is accessible
 by the sole named user only and that only 1 copy is accessed at any one time.
- A single paper copy may be printed for personal or internal company use only.

Standards purchased in hard copy format:

- A British Standard purchased in hard copy format is for personal or internal company use only.
- It may not be further reproduced in any format to create an additional copy.
 This includes scanning of the document.

If you need more than 1 copy of the document, or if you wish to share the document on an internal network, you can save money by choosing a subscription product (see 'Subscriptions').

Reproducing extracts

For permission to reproduce content from BSI publications contact the BSI Copyright & Licensing team.

Subscriptions

Our range of subscription services are designed to make using standards easier for you. For further information on our subscription products go to bsigroup.com/subscriptions.

With **British Standards Online (BSOL)** you'll have instant access to over 55,000 British and adopted European and international standards from your desktop. It's available 24/7 and is refreshed daily so you'll always be up to date.

You can keep in touch with standards developments and receive substantial discounts on the purchase price of standards, both in single copy and subscription format, by becoming a **BSI Subscribing Member**.

PLUS is an updating service exclusive to BSI Subscribing Members. You will automatically receive the latest hard copy of your standards when they're revised or replaced.

To find out more about becoming a BSI Subscribing Member and the benefits of membership, please visit bsigroup.com/shop.

With a **Multi-User Network Licence (MUNL)** you are able to host standards publications on your intranet. Licences can cover as few or as many users as you wish. With updates supplied as soon as they're available, you can be sure your documentation is current. For further information, email subscriptions@bsigroup.com.

Revisions

Our British Standards and other publications are updated by amendment or revision.

We continually improve the quality of our products and services to benefit your business. If you find an inaccuracy or ambiguity within a British Standard or other BSI publication please inform the Knowledge Centre.

Useful Contacts

Customer Services

Tel: +44 345 086 9001

Email (orders): orders@bsigroup.com **Email (enquiries):** cservices@bsigroup.com

Subscriptions

Tel: +44 345 086 9001

Email: subscriptions@bsigroup.com

Knowledge Centre

Tel: +44 20 8996 7004

Email: knowledgecentre@bsigroup.com

Copyright & Licensing

Tel: +44 20 8996 7070 Email: copyright@bsigroup.com

BSI Group Headquarters

389 Chiswick High Road London W4 4AL UK

